Literature DB >> 11955542

Terlipressin for norepinephrine-resistant septic shock.

Alastair O'Brien, Lucie Clapp, Mervyn Singer.   

Abstract

Norepinephrine-resistant hypotension when associated with septic shock has a high rate of mortality, which might possibly be reduced by infusion of low-dose vasopressin. However, rebound hypotension often arises after treatment is stopped, and the drug usually has to be administered for several days. We report use of terlipressin, a long-acting vasopressin analogue, in eight patients with septic shock who did not respond to corticosteroids and methylene blue. A significant rise in blood pressure that lasted for at least 5 h was seen in all patients after a single bolus, allowing reduction or cessation of norepinephrine administration in seven patients. We were able to discharge four patients from intensive care subsequently. Terlipressin seems to be an effective rescue therapy, which is able to restore blood pressure in patients with catecholamine-resistant septic shock, without obvious complication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955542     DOI: 10.1016/S0140-6736(02)08225-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  43 in total

1.  Comment on "Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?" by P. Asfar.

Authors:  Bart L De Keulenaer; Dianne P Stephens
Journal:  Intensive Care Med       Date:  2003-03-25       Impact factor: 17.440

2.  Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia.

Authors:  Matthias Lange; Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Gabriele Köhler; Tim G Kampmeier; Hugo Van Aken; Martin Westphal
Journal:  Inflamm Res       Date:  2010-12-29       Impact factor: 4.575

3.  Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?

Authors:  Andrea Morelli; Christian Ertmer; Matthias Lange; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

Review 4.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

5.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

Review 6.  The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients.

Authors:  E Christiaan Boerma; Can Ince
Journal:  Intensive Care Med       Date:  2010-09-02       Impact factor: 17.440

Review 7.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

8.  Admission plasma vasopressin levels in children with meningococcal septic shock.

Authors:  F Leclerc; E Walter-Nicolet; S Leteurtre; O Noizet; A Sadik; R Cremer; C Fourier
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

Review 9.  Recent advances in sepsis and septic shock.

Authors:  Praveen Khilnani; Satish Deopujari; Joe Carcillo
Journal:  Indian J Pediatr       Date:  2008-09-04       Impact factor: 1.967

10.  Terlipressin or europressin?

Authors:  Marc Leone
Journal:  Crit Care       Date:  2009-10-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.